We found that application of ACET (200–500 nM), a selective antagonist of GluK1 subunit containing KARs [28] resulted in a small but significant depression of the cortical EPSC in the control but not in the MS group (Supplementary Fig. 2A). The gene discussed is KARS1; the disease is myeloid sarcoma.